Brought to you by 
Bio-Rad buys MorphoSys's AbD Serotec division for €53mm in cash
31 Jan 2013
Executive Summary
In order to focus on its therapeutic antibody business, MorphoSys AG is divesting its research and diagnostic antibody unit AbD Serotec to Bio-Rad Laboratories Inc. (life science research and clinical diagnostics products distributor), which will pay €53mm ($69.8mm)--over three times the AbD segment’s 2012 sales.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bio-Rad buys MorphoSys's AbD Serotec division for €53mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice